Fresh2 Group Limited (FRES)

0.4226 +0.0091 (+2.20%) 收市：04:00PM EDT

Fresh2 Group Limited

650 5th Ave
Suite 2416
New York, NY 10019-6108
United States

https://fresh2.co

版塊: Healthcare
行業: Biotechnology
全職員工: 75

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Haohan Xu	Chairman of the Board & CEO	無	無	1995
Dr. He Yu	Co-Founder & Chief Scientist	無	無	1958
Ms. Xiaoyu Li	Director & CFO	無	無	1989
Mr. Weidong Dai	China President	無	無	1961
Dr. Sunil Pandit	U.S. Chief Executive Officer	無	無	無
Mr. Yidong Hu	Chief Strategy Officer	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.

公司管治

截至 無 止，Fresh2 Group Limited 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。